President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

The therapy was the first treatment to make it to market in the indication, closely followed by bluebird bio’s Lyfgenia (lovo-cel)—also a gene therapy. Less than six weeks later, Casgevy ...

Bluebird Bio’s Lyfgenia is listed at $3.1 million. Neither includes the cost of care to stay in the hospital or for chemotherapy. To manage the hefty price tag, insurers have implemented ...

The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...

bluebird could fare better with its new cell-based gene therapy for SCD, Lyfgenia (lovotibeglogene autotemcel), which was cleared by the FDA in December and has a list price of $3.1 million.

Its flagship product, LYFGENIA for SCD, is at the forefront of its commercialization efforts. LYFGENIA is a one-time gene therapy to treat sickle cell disease in individuals 12 years of age or ...

Since two gene therapies were approved for sickle cell disease in late 2023, only a handful of patients have started the expensive treatments.

CHOP doctors Thompson and Grupp have devoted their lives to improving the quality and length of life for children with sickle ...

Bluebird bio is a case study. The company has three approved gene therapies: Zynteglo for beta thalassemia, Skysona for cerebral adrenoleukodystrophy and Lyfgenia for sickle cell. Yet the firm has ...